Home » Stocks » CLPT

ClearPoint Neuro Inc. (CLPT)

Stock Price: $20.85 USD 0.85 (4.25%)
Updated Jul 29, 2021 4:00 PM EDT - Market closed
After-hours: $20.71 -0.14 (-0.67%) Jul 29, 4:20 PM
Market Cap 416.06M
Revenue (ttm) 13.74M
Net Income (ttm) -7.27M
Shares Out 20.76M
EPS (ttm) -0.44
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 29
Last Price $20.85
Previous Close $20.00
Change ($) 0.85
Change (%) 4.25%
Day's Open 20.00
Day's Range 19.78 - 20.98
Day's Volume 235,197
52-Week Range 3.48 - 31.29

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

ClearPoint Neuro, Inc. (CLPT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price...

3 days ago - Zacks Investment Research

If you are a growth investor, there is nothing more tantalizing than finding a company that could potentially grow by ten times or more in the future.

Other stocks mentioned: ASTS
3 days ago - The Dog of Wall Street

SOLANA BEACH, Calif. and SALT LAKE CITY, July 21, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and deli...

1 week ago - GlobeNewsWire

SOLANA BEACH, Calif., July 15, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, ...

2 weeks ago - GlobeNewsWire

Shares of a mobile esports company, a medical technology company, and a container-ship owner can be great additions to your portfolio in 2021.

Other stocks mentioned: GSL, SKLZ
1 month ago - The Motley Fool

SOLANA BEACH, Calif., June 16, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced ...

1 month ago - GlobeNewsWire

SOLANA BEACH, Calif., June 14, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, ...

1 month ago - GlobeNewsWire

First Ever Stem Cell Clinical Trial Patient Treated Using Entire ClearPoint Platform First Ever Stem Cell Clinical Trial Patient Treated Using Entire ClearPoint Platform

1 month ago - GlobeNewsWire

SOLANA BEACH, Calif., May 19, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, a...

2 months ago - GlobeNewsWire

SOLANA BEACH, Calif., May 18, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling company providing navigation and delivery to the brain, today anno...

2 months ago - GlobeNewsWire

SOLANA BEACH, Calif., May 11, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, t...

2 months ago - GlobeNewsWire

SOLANA BEACH, Calif., May 10, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, t...

2 months ago - GlobeNewsWire

ClearPoint Neuro, Inc. (CLPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

SOLANA BEACH, Calif., April 29, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain,...

3 months ago - GlobeNewsWire

SOLANA BEACH, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain,...

3 months ago - GlobeNewsWire

SOLANA BEACH, Calif., April 23, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain,...

3 months ago - GlobeNewsWire

SOLANA BEACH, Calif., April 13, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain,...

3 months ago - GlobeNewsWire

IRVINE, Calif., April 06, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today...

3 months ago - GlobeNewsWire

IRVINE, Calif., March 24, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today...

4 months ago - GlobeNewsWire

ClearPoint Neuro, Inc. (CLPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength...

4 months ago - Zacks Investment Research

ClearPoint Neuro, Inc. (CLPT) delivered earnings and revenue surprises of 30.77% and 0.43%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Shares of ClearPoint Neuro (NASDAQ:CLPT) were flat in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 18.18% over the past year to ($0.09), which be...

4 months ago - Benzinga

Company Reports Record Revenues

4 months ago - GlobeNewsWire

IRVINE, Calif., Feb. 23, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today ...

5 months ago - GlobeNewsWire

IRVINE, Calif., Feb. 19, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today ...

5 months ago - GlobeNewsWire

ClearPoint Neuro Inc (NASDAQ: CLPT) has priced its underwritten public offering of 1.85 million shares at $23.50 per share, representing a 9% discount on the last close price of $25.80 on Thursday. Gros...

5 months ago - Benzinga

IRVINE, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, announ...

5 months ago - GlobeNewsWire

IRVINE, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, announ...

5 months ago - GlobeNewsWire

Collaboration will Enable ClearPoint to Develop and Launch the ClearPoint ‘Maestro™' Brain Model by 2022

5 months ago - GlobeNewsWire

Partnership Enables ClearPoint Neuro to Compete in New and Complementary Markets Partnership Enables ClearPoint Neuro to Compete in New and Complementary Markets

5 months ago - GlobeNewsWire

IRVINE, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”) today announced that R. John Fletcher has been appointed Chairman of the Company's Board of Direct...

5 months ago - GlobeNewsWire

MRI Interventions, Inc. (CLPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

IRVINE, Calif., Jan. 26, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that E...

6 months ago - GlobeNewsWire

IRVINE, Calif., Jan. 14, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT), a global therapy-enabling platform company providing navigation and delivery to the brain, today reported the fir...

6 months ago - GlobeNewsWire

IRVINE, Calif., Jan. 12, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today ...

6 months ago - GlobeNewsWire

Represents Draw of Additional Proceeds from Petrichor Announced in January 2020 Represents Draw of Additional Proceeds from Petrichor Announced in January 2020

6 months ago - GlobeNewsWire

IRVINE, Calif., Nov. 30, 2020 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT), a leader in image-guided stereotactic neurosurgery, announced that its 4,000th neurosurgical procedure using the ...

7 months ago - GlobeNewsWire

IRVINE, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT), a medical device company with a portfolio of products focused on enabling therapies for neurological disorders, t...

8 months ago - GlobeNewsWire

About CLPT

ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system, a neuro-navigation system designed for instruments or devices designed to treat various neurological diseases and conditions, as well as for performing biopsies. In addition, the company's product pipeline includes ClearTrace system, ... [Read more...]

Industry
Medical Devices
Founded
1998
Stock Exchange
NASDAQ
Ticker Symbol
CLPT
Full Company Profile

Financial Performance

In 2020, CLPT's revenue was $12.83 million, an increase of 14.37% compared to the previous year's $11.22 million. Losses were -$6.78 million, 22.4% more than in 2019.

Financial Statements

Analyst Forecasts

According to one analyst, the rating for CLPT stock is "Strong Buy" and the 12-month stock price forecast is 35.00.

Price Target
$35.00
Analyst Consensus: Strong Buy